Allogeneic mesenchymal stem cells
Allogeneic mesenchymal stem cells has been studied in 1 paper since 2017: 1 trial in people. The newest paper, Oct 5, 2017: “Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial”.
1 paper studies it6 findingsUpdated
“No therapy-related TE-SAEs occurred at 1 month.”
None of its findings points the other way.
- 1 lab in 1 country
- 1 trial, none about aging
- Funders: Boston University and 3 more
- 6 of 6 findings with company ties
- Human trial1
What did studies of Allogeneic mesenchymal stem cells find?
6Studies of Allogeneic mesenchymal stem cells measured 6 outcomes; the most studied are early and late activated T-cells (1 study), B cell intracellular TNF-α (1) and serum TNF-α (1).
Early and late activated T-cells
downin humans1
1 study
Early and late activated T-cells
downin humans1
Allogeneic mesenchymal stem cells decrease early and late activated T-cells in humans.
“Early and late activated T-cells were also reduced by MSC therapy.”
Human trialaging frailty6 months postinfusion
The journals of gerontology. Series A, Biological sciences and medical sciences
B cell intracellular TNF-α
downin humans1
1 study
B cell intracellular TNF-α
downin humans1
Allogeneic mesenchymal stem cells decrease B cell intracellular TNF-α in humans (p < .0001 and p = .002; p = .003 and p = .039 versus placebo).
“B cell intracellular TNF-α improved in both the 100M- (p < .0001) and 200M-groups (p = .002) as well as between groups compared to placebo (p = .003 and p = .039, respectively).”
Human trialaging frailty100 or 200 million cells6 months postinfusion
The journals of gerontology. Series A, Biological sciences and medical sciences
Serum TNF-α
downin humans1
1 study
Serum TNF-α
downin humans1
Allogeneic mesenchymal stem cells decrease serum TNF-α in humans (p = .03).
“Serum TNF-α levels decreased in the 100M-group (p = .03).”
Human trialaging frailty100-million-cell intravenous infusion100 million cells6 months postinfusion
The journals of gerontology. Series A, Biological sciences and medical sciences
Female sexual quality of life
upin humans1
1 study
Female sexual quality of life
upin humans1
Allogeneic mesenchymal stem cells improve female sexual quality of life in humans (p = .03).
“The female sexual quality of life questionnaire improved in the 100M-group (p = .03).”
Human trialaging frailty100-million-cell intravenous infusion100 million cells6 months postinfusionfemales
The journals of gerontology. Series A, Biological sciences and medical sciences
Physical function
upin humans1
1 study
Physical function
upin humans1
Allogeneic mesenchymal stem cells improve physical function in humans (p = .01).
“The 6-minute walk test, short physical performance exam, and forced expiratory volume in 1 second improved in the 100M-group (p = .01), not in the 200M- or placebo groups.”
Human trialaging frailty100-million-cell intravenous infusion100 million cells6 months postinfusion
The journals of gerontology. Series A, Biological sciences and medical sciences
Treatment-emergent serious adverse events
no changein humans1
1 study
Treatment-emergent serious adverse events
no changein humans1
Allogeneic mesenchymal stem cells have no effect on treatment-emergent serious adverse events in humans (no therapy-related TE-SAEs at 1 month).
“No therapy-related TE-SAEs occurred at 1 month.”
Human trialaging frailty1 month postinfusion
The journals of gerontology. Series A, Biological sciences and medical sciences